Author

Christina M. Annunziata

Principal Investigator, National Cancer Institute - Cited by 7,569 - cancer

Biography

Dr. Annunziata established mechanisms underlying NF-kappaB molecular signal transduction in ovarian cancer. Her genomic profiling and functional screens identified both downstream targets and upstream regulators of this pathway, defining subgroups of patients whose cancers depend on NF-kappaB, and opening up possibilities for novel therapies to treat ovarian cancer. Her clinical trials emphasize collection of patient samples to better understand both predictive and pharmacodynamic markers of treatment response.
Title
Cited by
Year
Rapid image deconvolution and multiview fusion for optical microscopy
M Guo, Y Li, Y Su, T Lambert, DD Nogare, MW Moyle, LH Duncan, ...Nature biotechnology 38 (11), 1337-1346, 2020202
90
2020
Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers
BF Miller, TR Pisanic II, G Margolin, HM Petrykowska, P Athamanolap, ...Clinical epigenetics 12, 1-19, 2020202
66
2020
Driving immune responses in the ovarian tumor microenvironment
F Ning, CB Cole, CM AnnunziataFrontiers in Oncology 10, 604084, 2021202
22
2021
The ASTRO clinical practice guidelines in cervical cancer: optimizing radiation therapy for improved outcomes
J Chino, CM Annunziata, S Beriwal, L Bradfield, BA Erickson, EC Fields, ...Gynecologic oncology 159 (3), 607-610, 2020202
21
2020
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment
JM Lee, CM Annunziata, JL Hays, L Cao, P Choyke, M Yu, D An, ...Gynecologic oncology 159 (1), 88-94, 2020202
17
2020
Development and characterization of an anti-cancer monoclonal antibody for treatment of human carcinomas
K Tsang, M Fantini, SA Mavroukakis, A Zaki, CM Annunziata, PM ArlenCancers 14 (13), 3037, 2022202
8
2022
Disulfiram transcends ALDH inhibitory activity when targeting ovarian cancer tumor-initiating cells
MW Caminear, BS Harrington, RD Kamdar, MJ Kruhlak, CM AnnunziataFrontiers in Oncology 12, 62820, 2022202
7
2022
Mitochondrial matrix protease ClpP agonists inhibit cancer stem cell function in breast cancer cells by disrupting mitochondrial homeostasis
YE Greer, L Hernandez, EMJ Fennell, M Kundu, D Voeller, R Chari, ...Cancer research communications 2 (10), 1144-111, 2022202
6
2022
Intraperitoneal monocytes plus IFNs as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results from a phase I clinical trial
DS Green, F Ning, A Duemler, TG Myers, K Trewhitt, I Ekwede, A McCoy, ...Clinical Cancer Research 29 (2), 349-363, 2023202
5
2023
Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism
LF Hernandez, AB Dull, S Korrapati, CM AnnunziataCell Death Discovery 7 (1), 134, 2021202
5
2021
Matrix drug screen identifies synergistic drug combinations to augment smac mimetic activity in ovarian cancer
AM Noonan, A Cousins, D Anderson, KP Zeligs, K Bunch, L Hernandez, ...Cancers 12 (12), 378, 2020202
4
2020
Prenatal DNA sequencing for fetal aneuploidy also detects maternal cancer: importance of timely workup and management in pregnant women
AE Turriff, CM Annunziata, DW BianchiJournal of Clinical Oncology 0 (22), 2398-201, 2022202
4
2022
Pilot study assessing tolerability and metabolic effects of metformin in patients with Li-Fraumeni syndrome
FL Walcott, PY Wang, CM Bryla, RD Huffstutler, N Singh, MN Pollak, ...JNCI Cancer Spectrum (6), pkaa063, 2020202
4
2020
840 A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated …
K Tsang, M Fantini, C Cole, C Annunziata, P ArlenJournal for ImmunoTherapy of Cancer 9 (Suppl ), A881-A881, 010
2
2021
Another wrinkle with age: Aged collagen and intra‐peritoneal metastasis of ovarian cancer
EI Harper, TS Hilliard, EF Sheedy, P Carey, P Wilkinson, MD Siroky, ...Aging and cancer 3 (2), 6-29, 2022202
1
2022
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-20KY Tsang, M Fantini, A Zaki, SA Mavroukakis, MP Morelli, CM Annunziata, ...Cancers 4 (20), 4999, 2022202
1
2022
Overcoming ovarian cancer chemoresistance
G Samimi, C AnnunziataAcademic Press, 2020202
1
2020
637 Phase IIa combining NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors
637 Phase IIa combining NEO-20 with pembrolizumab in adults with chemo-resistant solid tumorsP Mark-Adjeli, C Annunziata, C Cole, MP Morelli, A McCoy, M Fantini, ...Journal for ImmunoTherapy of Cancer 0 (Suppl 2), 2022202
1
2022
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
First-in-human phase clinical trial of anti-core O-glycans targeting monoclonal antibody NEO-20 in treatment-refractory solid tumorsCB Cole, MP Morelli, M Fantini, M Miettinen, P Fetsch, C Peer, WD Figg, ...Journal of Experimental & Clinical Cancer Research 42 (), 76, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=ed3nqJEAAAAJ&hl=en

Cited by
Citations 7569
h-index 48
i10-index 93
Recommended Journals
Open Access Journals